The biopharmaceutical company Apogenix GmbH today announced the successful completion of a € 7.5 million financing round led by dievini Hopp BioTech holding GmbH & Co. KG (dievini). Other investors include the German Cancer Research Center (DKFZ), the founders and the executive management team of Apogenix. These funds will enable Apogenix to further advance the phase II clinical trial of APG101 to treat Glioblastoma Multiforme (GBM) and other cancer indications.
APG101 is a first-in-class, fully human protein that provides an innovative therapeutic approach to treating solid tumors such as GBM. APG101 is the most advanced inhibitor of the CD95 ligand (CD95L) in clinical development. In September 2011, Apogenix announced the completion of patient recruitment of its phase II clinical trial in GBM. Final results of this trial are expected in the first quarter of 2012.”APG101 has great potential to treat Glioblastoma patients, a disease with very few treatment options. With the sustained support of our existing investors, we can continue to exploit the therapeutic potential of this innovative compound”, said Dr Thomas Höger, CEO/CFO of Apogenix. “Based on the phase II GBM data, we will approach potential partners to explore their interest in the therapeutic and economic potential of APG101.”Dr Friedrich von Bohlen, Chairman of the Board of Apogenix and Managing Director of dievini commented: “We are very pleased with the progress of the APG101 program that is expected soon to show clinical proof-of-concept. Based on existing data and findings, everyone at Apogenix is excited about the therapeutic and commercial potential of this novel compound and treatment option for the most common and aggressive type of primary brain tumor as well as other solid tumors.”
More information:Dr. Thomas HögerCEO/CFOApogenix GmbHTel: +49 (6221) 5 86 08-0 Email: contact(at)apogenix.com